Hospital-acquired infection
of cases related with medical devices
Antibiotic-resistant bacteria
deaths in Europe each year
Antibiotic resistance
deaths expected worldwide by 2050
OUR STORY
SPARTHA Medical is a spin-off from INSERM UMR1121 a public research institute with more than 20 years of experience in development of engineered coatings.
SPARTHA Medical’s core technologies are patented-based inventions coming from two European projects (IMMODGEL and PANBioRA) that started in 2013.
OUR TEAM
Our Multidisciplinary Team brings together Know-How and Expertise
| Medical Device Design and Development
| Coating Technologies
| BioTechnology Business Development
| Production and Regulatory Affairs
OUR SUPPORTS
Spartha Medical has a strong support from :
| University of Strasbourg | SATT Conectus | INSERM| Biovalley France.
We financially supported by | Grand Est region (Start-up support) | French Public Bank of Investment (BPI France, i-Lab 2019) | and European Union
OUR PAGE ON STRASBOURG’S BIOMEDECINE CENTRE, WHERE OUR LABS ARE
If you’re looking for an internship biotech Strasbourg, Spartha Medical offers a unique opportunity to join a deep‑tech company developing bio‑intelligent materials for infection prevention. Based in Strasbourg, Spartha Medical operates at the intersection of biotechnology, data science, and medical … Read More
Spartha’s 2025 Gender Equality Plan: Building a Fair and Inclusive Workplace for Everyone At Spartha Medical, innovation is not only technological, it is also human. As we continue to grow and take on ambitious scientific and industrial challenges, we believe … Read More
Spartha Medical: Bio Intelligent Innovation for a Sustainable Future At Spartha Medical, we believe materials can do more than just exist, they can adapt, respond, and protect. Our mission is to turn that belief into reality with bio-intelligent surfaces designed … Read More
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Directorate-General for Communications Networks, Content and Technology. Neither the European Union nor the granting authority can be held responsible for them.